By Nana O 
High-grade glioma, a devastating and aggressive form of brain cancer that affects both children and adults, presents a formidable challenge to the medical community. Its insidious nature stems from several critical factors: the critical and often inaccessible locations of tumors within the brain, a high incidence of recurrence even after aggressive treatment, and the significant hurdle of the blood-brain barrier, which severely limits the efficacy of many therapeutic drugs. In a significant stride towards overcoming these obstacles, a collaborative team of researchers from the University of Michigan, Dana Farber Cancer Institute, and the Medical University of Vienna has unveiled a potential new therapeutic avenue, offering a glimmer of hope for patients battling this formidable disease.
Unveiling a Promising Target: PDGFRA Gene Alterations
The groundbreaking research, meticulously detailed in a recent publication in the prestigious journal Cancer Cell, has identified a specific genetic vulnerability within high-grade glioma tumors that can be exploited by a readily available drug. The study demonstrates that tumors harboring DNA alterations in the PDGFRA gene exhibit a remarkable response to avapritinib. This drug, already approved by the United States Food and Drug Administration (FDA), has a proven track record in treating other conditions, specifically gastrointestinal stromal tumors (GIST) with a PDGFRA exon 18 mutation, as well as advanced, indolent, and systemic mastocytosis.
"We were incredibly excited to observe that avapritinib effectively shut down PDGFRA signaling in mouse models of brain tumors," stated Dr. Carl Koschmann, a leading figure in pediatric brain tumor research and the study’s clinical scientific director at the Chad Carr Pediatric Brain Tumor Center at C.S. Mott Children’s Hospital. His sentiment underscores the pivotal nature of this finding, moving beyond the limited treatment options currently available.
The Longstanding Challenge of High-Grade Glioma Treatment
For decades, the therapeutic landscape for high-grade gliomas has been starkly limited. Beyond surgical resection and radiation therapy, which often prove insufficient to eradicate the disease or prevent its return, effective pharmacological interventions have been scarce. This scarcity is amplified by the recurrence rates, which are alarmingly high, leaving patients with few recourse options. The inherent difficulty for drug molecules to penetrate the brain’s protective blood-brain barrier further compounds these challenges, acting as a biological fortress against many potential treatments.
Recognizing this critical unmet need, Dr. Koschmann and his collaborators strategically focused their investigation on the PDGFRA gene. This gene emerged as a prime candidate due to its frequent involvement in the genetic mutations observed in high-grade gliomas, presenting a potential gateway to discovering novel drug therapies.
A Systematic Approach to Drug Discovery
The research team embarked on a systematic screening process, evaluating a wide array of commercially available drugs known to inhibit PDGFRA. This methodical approach led to the identification of avapritinib as the most potent and highly specific inhibitor targeting the PDGFRA alterations found in these aggressive tumors.
"We had been conducting extensive screens with numerous commercially available drugs that inhibit PDGFRA," explained Dr. Koschmann. "Our findings consistently pointed to avapritinib as the strongest and most precisely targeted inhibitor available for PDGFRA alterations."
Overcoming the Blood-Brain Barrier: A Crucial Breakthrough
A significant hurdle in developing effective brain cancer therapies is the blood-brain barrier, a highly selective physiological barrier that protects the central nervous system from circulating toxins and pathogens. However, it also impedes the passage of most therapeutic agents. The research team, in conjunction with colleagues from the laboratories of Dr. Mariella Filbin at Dana Farber Cancer Institute and Dr. Johannes Gojo at the Medical University of Vienna, who were independently investigating the efficacy of PDGFRA inhibitors, made a pivotal discovery: avapritinib possesses the crucial ability to cross this formidable barrier.
Kallen Schwark, a U-M M.D./Ph.D. student and one of the study’s lead authors, highlighted the significance of this finding: "When we administered the drug to mice and confirmed its presence in the brain, we knew we were on the verge of a significant breakthrough." This confirmation provided the essential validation for moving forward with further investigations.
Early Clinical Trials and Promising Patient Outcomes
The promising preclinical data paved the way for the treatment of several patients diagnosed with high-grade glioma through an expanded access program facilitated by Blueprint Medicines, the developer of avapritinib, while a formal clinical trial was still in its nascent stages.
"Across multiple international institutions, we had the opportunity to treat the first eight patients diagnosed with high-grade glioma using avapritinib," Dr. Koschmann reported. The initial results from this compassionate use initiative have been encouraging. "The patients tolerated the drug well, and in three of the eight patients, we observed a notable shrinkage of their tumors."
This preliminary clinical data, combined with the robust preclinical findings, served as the crucial evidence base for the inclusion of pediatric high-grade glioma in a Phase I pediatric solid tumor trial. This trial has recently completed patient accrual, and the analysis of its outcomes is currently underway, representing a critical next step in validating avapritinib’s potential.
"We have very few instances where drugs have successfully entered brain tumors and effectively suppressed key oncogenic pathways," Dr. Koschmann emphasized. "These results lend substantial support to ongoing efforts aimed at building upon the success of avapritinib and other brain-penetrant small molecule inhibitors."
The Prognosis and the Path Forward
High-grade gliomas are characterized by their aggressive nature, often carrying a grim prognosis of less than two years and a severe lack of effective treatment options. While the current work with avapritinib is preliminary, Dr. Koschmann expressed cautious optimism that this drug could become a valuable addition to the armamentarium available to clinicians.
However, he also underscored the complexity of combating such a tenacious disease: "We understand that a single drug is unlikely to be sufficient to conquer this disease." The path to truly significant progress, he believes, lies in a multifaceted approach. "The way to achieve meaningful advancements will involve combining various treatment modalities, such as integrating drugs that target pathways activated by the initial treatment."
The research team is already exploring such synergistic strategies, with ongoing work focused on combining avapritinib with MAP kinase inhibitors. This follow-up research is generating a similar level of excitement within the scientific community, indicating a proactive and forward-thinking approach to tackling high-grade gliomas.
Broader Implications for Neuro-Oncology
The successful demonstration of avapritinib’s ability to cross the blood-brain barrier and target specific genetic alterations in high-grade gliomas has far-reaching implications for the field of neuro-oncology. It validates the strategy of targeting specific driver mutations within brain tumors and highlights the importance of developing drugs with favorable pharmacokinetic properties for brain penetration.
This research could pave the way for similar investigations into other genetic alterations common in brain cancers. The identification of targetable pathways, coupled with the development of drugs that can effectively reach and act within the brain, offers a promising paradigm shift in how these devastating diseases are approached.
Future Directions and Collaboration
The collaborative nature of this research, involving institutions from multiple countries, exemplifies the global effort required to tackle complex diseases like high-grade glioma. The continued analysis of the ongoing Phase I trial data will be critical in determining the precise role of avapritinib in the treatment of pediatric high-grade glioma.
Furthermore, the development of new drug combinations, as indicated by the research into MAP kinase inhibitors, suggests a robust pipeline of innovation. By understanding the intricate molecular mechanisms driving tumor growth and recurrence, researchers can devise more sophisticated and effective therapeutic strategies.
The journey from laboratory discovery to clinical application is often long and arduous, but the findings presented in Cancer Cell represent a significant and encouraging step forward. The promise of avapritinib, coupled with the ongoing commitment to collaborative research and the development of novel treatment combinations, offers renewed hope for patients and families affected by high-grade gliomas, a disease that has long been characterized by its devastating impact and limited therapeutic options. The scientific community will be closely watching as this promising research continues to unfold, potentially transforming the future of brain cancer treatment.